Compare Becton Dickinson and Co (BDX) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Koninklijke Philips NV — how do they compare? Becton Dickinson and Co trades at $179.37 (market cap $49.41B), while Koninklijke Philips NV trades at $26.67 (market cap $26.58B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Koninklijke Philips NV pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| BDX | PHG | |
|---|---|---|
Market Cap | $49.41B | $26.58B |
Sector | Health | Health |
52-Week High | $185.39 | $32.91 |
52-Week Low | $138.62 | $25.02 |
Enterprise Value | $65.51B | $33.13B |
Dividend Yield | 2.32% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
PHG trades at $26.94, up 0.79% with bullish technical signals and strong earnings beats in recent quarters. The company shows improving fundamentals with 2025 net income of $895M (5.01% margin) and positive cash flow trends. Recent news highlights Exor's increased stake flexibility and institutional buying interest, supporting positive sentiment despite some order timing challenges.
The outlook remains constructive with analyst consensus leaning positive (40.9% buy ratings) and improving profitability. Key risks include competitive pressures and macroeconomic headwinds, but solid execution and shareholder support provide stability for medium-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
